Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
Manish A. Shah(NewYork–Presbyterian Hospital), Ken Kato(National Cancer Center Hospital East), Heung Tae Kim(Chungnam National University), Sung‐Bae Kim(Ulsan College), Masahiro Tajika(Aichi Cancer Center), Florian Lordick(Leipzig University), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), A. Craig Lockhart(Washington University in St. Louis), Per Pfeiffer(University of Southern Denmark), Judith Raimbourg(Institut de Cancérologie de l'Ouest), Farid El-Hajbi(Centre Oscar Lambret), Takashi Kojima(National Cancer Center Hospital East), Daniel Hochhauser(Royal London Hospital), Antoine Hollebecque(Institut Gustave Roussy), Peter C. Enzinger(Dana-Farber Cancer Institute), Hendrik-Tobias Arkenau(University College London), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mukul Gupta(Sansum Medical Clinic), Qi Liu(Southwest University)
Cited by 518
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k